NRAS and colorectal carcinoma: However, when pooling all target mutations (<i>KRAS, NRAS</i> and <i>BRAF</i>), the overall sensitivity and specificity were lower, at 48.3% and 51.1%, respectively.<h4>Conclusion</h4>The results of this study indicate that the ddPCR analysis of ctDNA may provide complementary information for the molecular diagnosis of CRC patients.